Petralia P, Kakkar Ajay K
Department of Surgical Oncology and Technology, Imperial College, Hammersmith Hospital, Du Cane Road, W12 0NN, London, UK.
Eur J Med Res. 2004 Mar 30;9(3):119-24.
Thrombosis is a common complication in patients with cancer. Low molecular weight heparins have been shown to be effective in both the prevention and treatment of venous thromboembolism in the cancer patient. More recently, studies have confirmed the benefits of extended duration of LMWH in the primary prevention of VTE after cancer surgery and for up to six months therapy for acute symptomatic VTE treatment. Beyond these well established uses for LMWH in the prevention and treatment of thrombosis in cancer patients, contemporary studies have demonstrated that LMWH therapy can prolong survival in patients with solid tumour malignant disease.
血栓形成是癌症患者常见的并发症。低分子量肝素已被证明在预防和治疗癌症患者的静脉血栓栓塞方面有效。最近，研究证实了延长低分子量肝素使用时间在癌症手术后原发性预防静脉血栓栓塞以及急性症状性静脉血栓栓塞治疗长达六个月的益处。除了低分子量肝素在预防和治疗癌症患者血栓形成方面这些已确立的用途外，当代研究表明，低分子量肝素治疗可延长实体瘤恶性疾病患者的生存期。
